EP2929041A4 - OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE - Google Patents

OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE

Info

Publication number
EP2929041A4
EP2929041A4 EP13861394.8A EP13861394A EP2929041A4 EP 2929041 A4 EP2929041 A4 EP 2929041A4 EP 13861394 A EP13861394 A EP 13861394A EP 2929041 A4 EP2929041 A4 EP 2929041A4
Authority
EP
European Patent Office
Prior art keywords
omega
associated methods
acid compositions
pentaenoic acid
pentaenoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13861394.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2929041A1 (en
Inventor
George Bobotas
Abdel Aziz Fawzy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Priority to EP21170003.4A priority Critical patent/EP3888646A1/en
Publication of EP2929041A1 publication Critical patent/EP2929041A1/en
Publication of EP2929041A4 publication Critical patent/EP2929041A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B20/00—Preservation of edible oils or fats
    • A23B20/30—Preservation of other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B5/00—Preserving by using additives, e.g. anti-oxidants
    • C11B5/0007—Organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
EP13861394.8A 2012-12-06 2013-12-06 OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE Withdrawn EP2929041A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21170003.4A EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734331P 2012-12-06 2012-12-06
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/073701 WO2014089501A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21170003.4A Division EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Publications (2)

Publication Number Publication Date
EP2929041A1 EP2929041A1 (en) 2015-10-14
EP2929041A4 true EP2929041A4 (en) 2016-06-08

Family

ID=50884050

Family Applications (3)

Application Number Title Priority Date Filing Date
EP13861394.8A Withdrawn EP2929041A4 (en) 2012-12-06 2013-12-06 OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE
EP13861305.4A Withdrawn EP2928462A4 (en) 2012-12-06 2013-12-06 METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
EP21170003.4A Withdrawn EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP13861305.4A Withdrawn EP2928462A4 (en) 2012-12-06 2013-12-06 METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
EP21170003.4A Withdrawn EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Country Status (9)

Country Link
EP (3) EP2929041A4 (enExample)
JP (4) JP6881893B2 (enExample)
KR (3) KR20150103009A (enExample)
CN (4) CN112107570A (enExample)
AU (7) AU2013354979A1 (enExample)
CA (2) CA2894366A1 (enExample)
IN (2) IN2015MU01505A (enExample)
MX (2) MX2015007085A (enExample)
WO (2) WO2014089501A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101568665B1 (ko) 2015-07-21 2015-11-12 디와이오토 주식회사 모터의 맥동 전류를 증가시키는 브러시 구조
WO2018001844A1 (en) * 2016-06-28 2018-01-04 Nestec S.A. Biomarkers of blood-brain barrier dysfunction
JP2018168139A (ja) * 2016-10-21 2018-11-01 マルハニチロ株式会社 ｎ−３系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるｎ−３系不飽和脂肪酸の使用
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
EP3586643A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586641A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002125618A (ja) * 2000-10-30 2002-05-08 Katsuyuki Wakatsuki 健康食品
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
JP5658876B2 (ja) * 2006-07-05 2015-01-28 フォトンズ コーポレーション リミテッド 大規模従属栄養培養領域にて産生される超高純度ｅｐａと極性脂質
CN102421422A (zh) * 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
BRPI1011883A2 (pt) * 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
JP2014505729A (ja) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ）
JP2014505732A (ja) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患において用いるための、スタチンおよびω３脂肪酸（ＥＰＡ、ＤＨＡおよびＤＰＡ）

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014089501A1 *

Also Published As

Publication number Publication date
CA2894183A1 (en) 2014-06-12
WO2014089511A2 (en) 2014-06-12
KR20210059779A (ko) 2021-05-25
KR20150103009A (ko) 2015-09-09
AU2017232203A1 (en) 2017-10-12
JP2016501248A (ja) 2016-01-18
AU2018229440A1 (en) 2018-10-04
EP3888646A1 (en) 2021-10-06
CN104902888A (zh) 2015-09-09
AU2021201865A1 (en) 2021-04-22
WO2014089511A3 (en) 2014-07-31
IN2015MU01505A (enExample) 2016-05-27
MX2015007082A (es) 2016-01-12
EP2928462A2 (en) 2015-10-14
IN2015DE05009A (enExample) 2015-12-18
CN112107570A (zh) 2020-12-22
AU2019216634A1 (en) 2019-09-05
JP2021120407A (ja) 2021-08-19
AU2020203658A1 (en) 2020-06-25
JP6881893B2 (ja) 2021-06-02
WO2014089501A1 (en) 2014-06-12
EP2928462A4 (en) 2016-06-01
JP2016501249A (ja) 2016-01-18
CA2894366A1 (en) 2014-06-12
CN104937103A (zh) 2015-09-23
MX2015007085A (es) 2016-01-12
EP2929041A1 (en) 2015-10-14
JP2019172697A (ja) 2019-10-10
CN113274378A (zh) 2021-08-20
KR20150103671A (ko) 2015-09-11
AU2013354969A1 (en) 2015-06-11
AU2013354979A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
FR24C1025I1 (fr) Compositions et méthodes de traitement de l'anémie
EP2934505A4 (en) EICOSAPENTAIC ACID (EPA) FORMULATIONS
EP2861227A4 (en) OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
EP2915557A4 (en) Retinoic acid-MICRO NEEDLE
DK3072510T3 (da) Omega-3-fedtsyreestersammensætninger
EP2834322A4 (en) BIOKOHLEZ COMPOSITIONS AND METHOD FOR USE THEREOF
EP2892562A4 (en) ANTI-MCAM ANTIBODIES AND ASSOCIATED METHOD FOR USE
EP2903939A4 (en) STABLE PERCARBOXYLIC ACID COMPOSITIONS AND USES THEREOF
EP2680886A4 (en) SUBSTITUTED CHINOLIN COMPOUNDS AND METHOD OF USE THEREOF
EP2804601A4 (en) COMPOSITIONS AND METHODS FOR USING PHOENIXES
DK3725778T4 (da) Formuleringer af enzalutamid
EP3735963C0 (en) SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACIDS
EP2841443A4 (en) SERPINC1 IRNA COMPOSITIONS AND METHOD OF USE THEREOF
EP2814895A4 (en) POST-CMP DISPOSAL USING COMPOSITIONS AND USE PROCESSES
EP2890772A4 (en) MULTIFUNCTIONAL COMPOSITIONS AND METHODS OF USE
EP2859111A4 (en) NUKLEINSÄUREAMPLIFIZIERUNGEN
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP2970961A4 (en) nucleic acid amplification
EP2897639A4 (en) IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE
EP2919788A4 (en) METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
EP2931313A4 (en) Solution Formulations of Genetically Engineered Anti- 23P19 Antibodies
FR3015290B1 (fr) Compositions d'acide hyaluronique compreant de la mepivacaine
EP2983661A4 (en) FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHENDS
EP3113613A4 (en) LIPOIC ACID CHOLINESTER COMPOSITIONS AND METHOD OF USE THEREOF
EP2969012A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING SEQUENCEL ANTIBODY-BONDED MICROBES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/40 20060101ALI20160429BHEP

Ipc: A61K 31/202 20060101ALI20160429BHEP

Ipc: A61K 31/225 20060101AFI20160429BHEP

Ipc: A23D 9/00 20060101ALI20160429BHEP

Ipc: C11B 5/00 20060101ALI20160429BHEP

Ipc: A61K 9/48 20060101ALI20160429BHEP

Ipc: A23D 9/06 20060101ALI20160429BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220701